- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2013
- Public Summary Document (PSD) November 2013 PBAC Meeting - PDF
Ranibizumab (dme) – November 2013
Ranibizumab, solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis®
Last updated
8 November 2023